[144] Lexeo Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) reported a Form 144 notice for the proposed sale of 382 common shares, with an aggregate market value of $1,783.25, to be sold on 08/18/2025 on NASDAQ. The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and were paid as compensation. The filing shows 54,001,214 shares outstanding and notes no securities sold by the filer in the past three months. The notice includes the standard representation that the seller has no undisclosed material adverse information.

Positive

• Filing complies with Rule 144, providing required disclosure for an insider sale
• No securities sold in prior three months by the filer, limiting immediate aggregated selling pressure

Negative

• None.

Insights

Securities Analyst

TL;DR Small, routine insider sale following restricted stock vesting; immaterial to company capitalization.

The Form 144 documents a modest sale of 382 shares resulting from restricted stock vesting and classified as compensation. At an aggregate value of $1,783.25 against 54,001,214 shares outstanding, this transaction is immaterial to market capitalization and unlikely to influence investor valuation. The filing complies with Rule 144 disclosure requirements and indicates no other sales in the prior three months, which reduces near-term selling pressure from this filer.

Corporate Governance Expert

TL;DR Governance processes appear followed: vested compensation converted to sale notice and disclosed under Rule 144.

The notice shows the issuer processed restricted stock vesting and the recipient intends to sell a small block of shares. The filer attests to absence of undisclosed material adverse information, and no additional recent sales are reported. Procedurally, the filing demonstrates adherence to insider sale disclosure protocols; there are no governance red flags disclosed in this form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	382	1783.25	54001214	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Vesting	Issuer			382	08/15/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Lexeo Therapeutics' Form 144 disclose about the planned sale?

The filing discloses a proposed sale of 382 common shares valued at $1,783.25, to occur on 08/18/2025 on NASDAQ.

How were the shares acquired that are being sold for LXEO?

The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and were paid as compensation.

How many Lexeo Therapeutics shares are outstanding according to the filing?

The filing lists 54,001,214 shares outstanding.

Did the filer report any securities sold in the past three months?

The Form 144 states "Nothing to Report" for securities sold during the past three months.

Does the filer claim any undisclosed material information about LXEO?

By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.